All the fundraising deals in the longevity market (from Q1 2025 to Q1 2026)
Download our beautiful pitch about the longevity market
In our longevity market deck, you will find everything you need to understand the market
The longevity market saw 18 publicly announced funding rounds between Q1 2025 and Q1 2026, totaling nearly $1.94 billion raised across therapeutics, diagnostics, and consumer health platforms.
A handful of mega-rounds dominated the headlines, but a steadier stream of seed and Series A deals showed that early-stage interest in the longevity market remains strong.
From epigenetic reprogramming drugs to biological age diagnostics, the longevity market is attracting capital from both traditional life science VCs and high-profile individual investors.
And if you want to better understand this new industry, you can download our pitch covering the longevity market.
Insights
- Q1 2025 was almost entirely defined by one deal: Retro Biosciences' $1B round alone represented 94.8% of that quarter's total longevity market funding, making it one of the largest single raises in biotech history.
- Human longevity therapeutics captured $1.37B, or about 70% of all longevity market funding over the 5-quarter period, confirming that investors still write their biggest checks for science targeting aging biology directly.
- Diagnostics and health data platforms in the longevity market raised $324.7M across just 4 deals, suggesting investors increasingly value businesses that can monetize longevity today rather than waiting years for a drug approval.
- NewLimit raised twice in 2025, first $130M in May and then an additional $45M in October, bringing its total to $175M in under 6 months and signaling unusually high conviction from investors in epigenetic reprogramming.
- Three longevity market deals in Q1 2026 already totaled $143.5M, putting the first quarter of 2026 on pace to exceed the combined activity of Q2 and Q3 2025.
- Loyal is the only company in this longevity market dataset to raise in two separate quarters, going from a $22M Series B-2 in Q1 2025 to a $100M Series C in Q1 2026, which reflects rapid commercial progress in canine longevity drugs.
- Consumer longevity brands like Blueprint, Decode Age, and L-Nutra collectively raised $98.2M, proving that science-branded healthspan products can attract meaningful venture capital even without a drug pipeline.
- The longevity market is becoming more geographically diverse, with MENA-linked investments in Juvenescence and L-Nutra, an Australian raise for TMRW, and an Indian round for Decode Age all appearing in the dataset.
- Khosla Ventures is the only investor in this longevity market dataset to appear in more than one distinct company's funding round, backing both NewLimit and Circulate Health.
- The mean deal size in the longevity market drops dramatically once you remove the top 1-2 rounds per quarter, falling to roughly $15-25M per deal, which is closer to typical deep-tech seed and Series A territory.
- Q3 2025 was the quietest quarter in the longevity market with only 2 deals and $30M raised, yet both deals were operationally focused (a clinic network and a plasma exchange provider), suggesting a brief rotation toward care delivery models.
In our longevity market deck, we will give you useful market maps and grids
Summary table of the funding deals in the longevity market (last 5 quarters)
We define the longevity market as products and services that use science, medicine, or technology to extend healthy years of life and slow or improve the effects of aging.
We include therapies, diagnostics, clinics, digital tools, supplements, and programs that are explicitly designed and marketed to improve healthspan, prevent age-related decline, or optimize long-term health.
We exclude generic healthcare, wellness, beauty, fitness, eldercare, and financial products that serve older adults but are not specifically focused on longevity or healthspan.
You can also read our detailed analysis to understand how funding activity in the longevity market has evolved over the last few years.
Also, you should know that we have a dedicated page, updated weekly, with all the latest fundraising deals in the longevity market.
| Name | What they do | Amount | Quarter | Source(s) |
|---|---|---|---|---|
| Cambrian Bio | Develops drugs targeting biological aging drivers to prevent disease and extend healthspan. | $23M | Q1 2025 | Crain's New York |
| Retro Biosciences | Builds therapeutics using cellular reprogramming to extend healthy human lifespan. | $1,000M | Q1 2025 | TechCrunch |
| Junevity | Develops siRNA-based cell reset therapeutics to restore healthy cell function and extend lifespan. | $10M | Q1 2025 | Business Wire |
| Loyal | Creates FDA-regulated drugs designed to extend dogs' healthy lifespan. | $22M | Q1 2025 | Longevity Technology |
| Juvenescence | Develops medicines targeting core aging mechanisms to extend human healthspan, with an Abu Dhabi partnership. | $150M | Q2 2025 | Juvlabs |
| NewLimit | Builds epigenetic reprogramming medicines to restore youthful function to aging cells. | $130M | Q2 2025 | TechCrunch |
| Circulate Health | Runs therapeutic plasma exchange programs to reduce inflammation and improve healthspan. | $12M | Q3 2025 | PR Newswire |
| Fountain Life | Operates prevention-first longevity centers combining advanced screening, AI guidance, and restorative therapies. | $18M | Q3 2025 | TechCrunch |
| NewLimit | Builds epigenetic reprogramming medicines to restore youthful function to aging cells (follow-on round). | $45M | Q4 2025 | Longevity Technology |
| Generation Lab | Sells a biological aging diagnostic called SystemAge that measures how different organs are aging. | $11M | Q4 2025 | PR Newswire |
| Blueprint | Packages Bryan Johnson's longevity protocol into a consumer platform covering testing, supplements, and health programs. | $60M | Q4 2025 | Longevity Technology |
| Function Health | Offers recurring lab testing, imaging, and AI-driven preventive health guidance for long-term health optimization. | $298M | Q4 2025 | TechCrunch |
| Junevity | Develops siRNA-based cell reset therapeutics to restore healthy cell function and extend lifespan (seed extension). | $10M | Q4 2025 | Business Wire |
| Decode Age | Develops India-based longevity diagnostics and supplements grounded in gut microbiome and aging science. | $1.7M | Q4 2025 | Startup News |
| GlycanAge | Uses glycan biomarkers to measure biological aging and chronic inflammation for preventive care. | $8.7M | Q4 2025 | Tech Funding News |
| L-Nutra | Develops science-backed nutrition programs and medical nutrition therapies designed to improve healthspan, with MENA expansion. | $36.5M | Q1 2026 | PR Newswire |
| Loyal | Creates FDA-regulated drugs designed to extend dogs' healthy lifespan (Series C). | $100M | Q1 2026 | Business Wire |
| TMRW | Australian longevity platform combining diagnostics, clinical support, and personalized biological age testing. | $7M | Q1 2026 | Longevity Technology |
In our longevity market deck, we identify pain points entrepreneurs should prioritize
How has funding activity in the longevity market changed over time?
Q1 2025 was by far the most active quarter in dollar terms, but that is almost entirely because of Retro Biosciences' $1B Series A, which alone accounted for 95% of the quarter's total.
Q3 2025 was the quietest quarter in the longevity market, with only 2 deals totaling $30M and no mega-round in sight.
Compared to Q4 2025, Q1 2026 raised 67% less ($143.5M vs $434.4M), but compared to Q1 2025 one year earlier, Q1 2026 raised 86% less ($143.5M vs $1,055M), driven entirely by the absence of a Retro-scale deal.
If you strip out the top deal each quarter, the underlying longevity market funding trend is actually quite stable, running between $30M and $140M per quarter, which suggests a healthy and consistent base of deal activity beyond the headline raises.
| Quarter | Number of deals | Total raised | Comment |
|---|---|---|---|
| Q1 2025 | 4 | $1,055M | Dominated by Retro Biosciences' $1B raise, the largest longevity market deal on record. |
| Q2 2025 | 2 | $280M | Two large deals in human longevity therapeutics: Juvenescence ($150M) and NewLimit ($130M). |
| Q3 2025 | 2 | $30M | Quietest quarter overall, focused on care delivery models rather than drug development. |
| Q4 2025 | 7 | $434.4M | Most active quarter by deal count, with Function Health's $298M raise pulling totals up significantly. |
| Q1 2026 | 3 | $143.5M | Solid start to 2026, with Loyal's $100M Series C and L-Nutra's MENA-backed $36.5M Series D. |
| All quarters | 18 | $1,942.9M | Total across 5 quarters, heavily skewed by two mega-rounds (Retro and Function Health). |
In our longevity market deck, we identify repeatable patterns you can use if you’re building in this market
Which startups in the longevity market raised the largest rounds over the last months?
These startups raised the most recently in the longevity market:
- Retro Biosciences raised $1B because Sam Altman and other backers made a high-conviction bet that cellular reprogramming can genuinely extend human lifespan, and the company needed capital to get multiple programs into the clinic fast.
- Function Health raised $298M at a $2.5B valuation because Redpoint Ventures and a16z saw a scalable platform for long-term health optimization through lab testing, imaging, and AI-driven preventive guidance.
- Juvenescence raised $150M because Abu Dhabi-based M42 made a strategic bet on AI-enabled longevity therapeutics and a MENA expansion partnership with the company.
- NewLimit raised $130M led by Kleiner Perkins because the Coinbase CEO Brian Armstrong-backed biotech showed compelling early results in epigenetic reprogramming and needed to accelerate its path to a first clinical trial.
- Loyal raised $100M led by age1 because the company reached major FDA milestones for its canine longevity drug, making it the closest thing to a commercially ready longevity therapeutic in the dataset.
- Blueprint raised $60M because Bryan Johnson attracted a high-profile investor syndicate including Naval Ravikant and the Winklevoss brothers who believed his "Don't Die" protocol could become a global consumer longevity platform.
- NewLimit raised an additional $45M in a strategic follow-on led by Eli Lilly because new technical breakthroughs in its reprogramming platform brought the company closer to starting its first human study.
- L-Nutra raised $36.5M from Mubadala Investment Company to launch a joint venture in Abu Dhabi and accelerate global expansion of its longevity nutrition programs.
- Cambrian Bio raised $23M in unattributed venture funding to advance its portfolio of anti-aging drug programs targeting the biological drivers of aging.
- Loyal raised $22M in a Series B-2 led by Valor Equity Partners and Collaborative Fund to move its canine longevity drug programs forward after an important FDA milestone.
And, yes, we do cover most of them in our beautiful pitch about the longevity market.
You may also want to check our ranking of the most funded startups in the longevity market as well as our list of the most valued startups.
In our longevity market deck, we answer all the common questions from investors and entrepreneurs
Is the longevity market shifting toward smaller or bigger deals?
Across all 18 longevity market deals in the dataset, the average round size is $107.9M, but that number is heavily distorted by two outliers: Retro Biosciences ($1B) and Function Health ($298M).
The average deal size per quarter swings dramatically: $263.8M in Q1 2025, $140M in Q2 2025, $15M in Q3 2025, $62.1M in Q4 2025, and $47.8M in Q1 2026, which mostly reflects whether a mega-round happened that quarter rather than any structural shift in longevity market valuations.
If you exclude the top two deals from the entire dataset, the remaining 16 longevity market rounds average just $41.5M, with most clustering between $7M and $60M, which is consistent with a market where early-stage and growth-stage deal flow is healthy but mega-rounds are rare events driven by exceptional conviction.
| Quarter | Number of deals | Average deal size | Deals below $2M | Deals above $50M |
|---|---|---|---|---|
| Q1 2025 | 4 | $263.8M | 0 | 1 |
| Q2 2025 | 2 | $140.0M | 0 | 2 |
| Q3 2025 | 2 | $15.0M | 0 | 0 |
| Q4 2025 | 7 | $62.1M | 1 | 2 |
| Q1 2026 | 3 | $47.8M | 0 | 1 |
| All quarters | 18 | $107.9M | 1 | 6 |
In our longevity market deck, we help you understand how the market is structured
How concentrated was funding activity in the longevity market?
Longevity market funding is extremely concentrated: in every single quarter, the top 1 deal captured between 54% and 95% of that quarter's total, which means a small number of high-conviction bets are driving the vast majority of capital flows. This pattern is consistent across all 5 quarters in the dataset.
Looking at the top 3 deals, they captured 100% of funding in 3 out of 5 quarters, confirming that the longevity market is still in a phase where a few large bets dominate and the long tail of smaller deals contributes only a modest share of total capital.
| Quarter | Number of deals | % by Top 1 | % by Top 3 | % by Top 10 |
|---|---|---|---|---|
| Q1 2025 | 4 | 94.8% | 99.1% | 100.0% |
| Q2 2025 | 2 | 53.6% | 100.0% | 100.0% |
| Q3 2025 | 2 | 60.0% | 100.0% | 100.0% |
| Q4 2025 | 7 | 68.6% | 92.8% | 100.0% |
| Q1 2026 | 3 | 69.7% | 100.0% | 100.0% |
| All quarters | 18 | 51.5% | 71.1% | 100.0% |
In our longevity market deck, we have designed useful charts to give you full market clarity
Which categories in the longevity market received the most funding?
Human longevity therapeutics captured $1.37B, or about 70% of total longevity market funding, across 7 deals including Retro Biosciences, NewLimit, Juvenescence, Junevity, and Cambrian Bio. Investors are still most willing to write their biggest checks when the pitch is about treating aging biology directly, especially through cell reprogramming.
Preventive diagnostics and health data platforms raised $324.7M across 4 deals including Function Health, Generation Lab, GlycanAge, and TMRW, making it the second-largest category. This is largely commercial-platform money rather than deep-science bets, signaling that investors increasingly like longevity businesses that can generate revenue now through testing and AI-driven health guidance.
Animal longevity therapeutics captured $122M across 2 deals, both from Loyal, which develops canine lifespan-extension drugs. The category is small in deal count but growing fast in dollar terms, going from a $22M round in Q1 2025 to a $100M Series C in Q1 2026 as Loyal got closer to a commercial product.
| Category name | Number of deals | Total raised | Startups and amount |
|---|---|---|---|
| Human longevity therapeutics | 7 | $1,368M | Cambrian Bio ($23M), Retro Biosciences ($1,000M), Junevity ($10M + $10M extension), Juvenescence ($150M), NewLimit ($130M + $45M) |
| Preventive diagnostics & health data platforms | 4 | $324.7M | Function Health ($298M), Generation Lab ($11M), GlycanAge ($8.7M), TMRW ($7M) |
| Animal longevity therapeutics | 2 | $122M | Loyal ($22M + $100M) |
In our longevity market deck, we cover the latest tech updates shaping the market
Who are the biggest investors in the longevity market?
Khosla Ventures is the most active institutional investor in this longevity market dataset, appearing in 2 distinct deals, NewLimit and Circulate Health, which reflects the firm's well-documented thesis that aging biology and longevity science are among the most important investment areas of the next decade.
Goldcrest Capital participated in both of Junevity's funding rounds, leading both the original $10M seed and the $10M extension, making it one of the most committed early-stage backers of longevity therapeutics in the dataset.
Godfrey Capital co-led both Junevity rounds alongside Goldcrest Capital, showing similar conviction in siRNA-based cell reset approaches to healthspan extension.
Disclaimer: this investor list may be incomplete; we focus on publicly disclosed lead and prominent recurring investors, so some frequent minority participants may be underrepresented. "Total funded" does not represent the amount personally invested by an individual investor. Instead, it refers to the aggregate amount raised across all fundraising rounds in which the investor participated.
| Investor | Number of deals | Total funded | Startups |
|---|---|---|---|
| Khosla Ventures | 2 | $142M | NewLimit ($130M), Circulate Health ($12M) |
| Goldcrest Capital | 2 | $20M | Junevity ($10M seed), Junevity ($10M extension) |
| Godfrey Capital | 2 | $20M | Junevity ($10M seed), Junevity ($10M extension) |
In our longevity market deck, we track adoption trends and shifts in consumer behavior
Related blog posts
- All the recent funding deals in the longevity market
- The startups that have raised the most funding in the longevity market
